세계의 세포 치료 기술 시장 : 제품별, 프로세스별, 세포 유형별, 용도별, 최종사용자별, 지역별 - 예측(-2029년)

The global cell therapy technologies market is projected to surpass USD 6.80 billion in 2029 from USD 4.03 billion in 2024, with a significant CAGR of 11.0%. This market is driven by advancements in regenerative medicine, the rising prevalence of chronic diseases, increasing investments in research and development, and innovations in gene editing tools, such as CRISPR. Regulatory support and government funding, alongside strategic collaborations between biotech firms and academic institutions, are propelling the development of novel cell therapies, subsequently driving the market growth.

"The T cells cell therapy technologies segment accounted for the largest share in 2023."

The cell therapy technologies market is bifurcated into three primary categories based on cell type, that are T cells, stem cells, and other cells. The T cells segment dominated the share of the market in the year 2023 due to being crucial in advancing immunotherapies, especially CAR-T therapies spurring substantial investments and technological innovations in T-cell engineering and scalable manufacturing. Advancements in CRISPR technology, ex vivo expansion, and "off-the-shelf" allogeneic solutions all further help in advancing market offerings.

"By application, the cancer application segment accounted for the largest share in the cell therapy technologies market."

The application segment in the cell therapy technologies market includes cancer, cardiovascular disease (CVD), orthopaedic disorders, autoimmune diseases, and other applications. The cancer application dominated the segment due to increasing prevalence of cancer globally and the rising demand for innovative, targeted therapies. Advancements in cell engineering, scalable manufacturing, and emerging applications in solid tumors further enhance the growth potential of this segment. It possesses a solid clinical pipeline, and the government initiatives are very supportive with regulatory approvals for the growth of the segment.

"North America: the largest share of the cell therapy technologies market"

By region, the market is segment into North America, Europe, Asia Pacific, Latin America, the Middle East and Africa. North America dominated the cell therapy technologies market in 2023 and likely continue to be dominant during the forecast period. North America dominates the cell therapy technologies market due to its robust healthcare infrastructure, significant investments in research and development, and the presence of key market players. The region benefits from strong regulatory support, with agencies like the FDA streamlining approvals for innovative therapies. High prevalence of chronic diseases, increasing demand for personalized medicine, and advanced manufacturing facilities further bolster regions dominance.

In-depth interviews have been conducted with chief executive officers (CEOs), Directors, and other executives from various key organizations operating in the cell therapy technologies market.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 70% and Demand Side 30%
• By Designation: Managers - 45%, CXO & Directors - 30%, and Executives - 25%
• By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5% and Middle East & Africa- 5%

Danaher Corporation (US), Merck KGaA (Germany), Thermo Fisher Scientific Inc. (US), Lonza (Switzerland), Sartorius AG (Germany), Agilent Technologies Inc. (US), Avantor, Inc. (US), Bio-Techne (US), Fresenius SE & Co KGAA (Germany), BD (US), Corning Incorporated (US), Terumo Corporation (Japan), GenScript (US), MaxCyte (US) and STEMCELL Technologies (Canada) are some of the major players operating in the cell therapy technologies market.

Research Coverage:

This research report categorizes the cell therapy technologies market product (media, sera, and reagents; cell engineering products; cell culture vessels; cell therapy equipment; systems & software; and other products), process (cell processing, cell preservation, cell distribution, cell handling, and process monitoring & quality control), cell type (T cells, stem cells, and other cells), application (cancer, cardiovascular disease (CVD), orthopedic disorders, autoimmune diseases, and other applications) end user (biopharmaceutical & biotechnology companies, CROs & CMOs, research institutes, and cell banks) and region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the cell therapy technologiess market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, key strategies, collaborations, partnerships, and agreements. New launches, collaborations and acquisitions, and recent developments associated with the cell therapy technologies market.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the cell therapy technologies and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

• Analysis of key drivers (increased funding and investment in cell therapy, advancements in gene editing technologies, the development of automated cell processing systems, and regulatory support for fast-tracking therapies), restraints (manufacturing and logistical complexity), opportunities (personalized and off-the-shelf cell therapies, integration with digital technologies such as AI & ML) and Challenges (supply chain & cold chain management and manufacturing scalability & quality control).
• Product Development/Innovation: Detailed insights on maintaining a comprehensive and innovative product portfolio offering for cell therapy technologies.
• Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the cell therapy technologies market.
• Competitive Assessment: Danaher Corporation (US), Merck KGaA (Germany), Thermo Fisher Scientific Inc. (US), Lonza (Switzerland), Sartorius AG (Germany), and among others in the market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
  • 2.1.2 PRIMARY DATA
• 2.2 MARKET ESTIMATION METHODOLOGY
  • 2.2.1 MARKET ESTIMATION
  • 2.2.2 INSIGHTS FROM PRIMARY EXPERTS
  • 2.2.3 SEGMENTAL MARKET ESTIMATION (TOP-DOWN APPROACH)
• 2.3 MARKET GROWTH RATE PROJECTIONS
• 2.4 DATA TRIANGULATION
• 2.5 RESEARCH ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
• 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 CELL THERAPY TECHNOLOGIES MARKET OVERVIEW
• 4.2 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT AND COUNTRY (2023)
• 4.3 CELL THERAPY TECHNOLOGIES MARKET SHARE, BY PRODUCT, 2024 VS. 2029
• 4.4 CELL THERAPY TECHNOLOGIES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Increased funding and investment in cell therapy
    • 5.2.1.2 Advancements in gene editing technologies
    • 5.2.1.3 Development of automated cell processing systems
    • 5.2.1.4 Regulatory support for fast-tracking therapies
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Manufacturing and logistical complexity
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Personalized and off-the-shelf cell therapies
    • 5.2.3.2 Integration with digital technologies such as AI & ML
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Supply chain & cold chain management and manufacturing scalability & quality control
• 5.3 ECOSYSTEM ANALYSIS
  • 5.3.1 PRODUCT PROVIDERS
  • 5.3.2 END USERS
  • 5.3.3 REGULATORY BODIES
• 5.4 TECHNOLOGY ANALYSIS
  • 5.4.1 KEY TECHNOLOGIES
    • 5.4.1.1 Magnetic-activated cell sorting
    • 5.4.1.2 Cryopreservation
    • 5.4.1.3 Gene editing technologies
    • 5.4.1.4 Bioprocessing technologies
  • 5.4.2 COMPLEMENTARY TECHNOLOGIES
    • 5.4.2.1 Artificial intelligence and machine learning
    • 5.4.2.2 Biomaterials and scaffolding
    • 5.4.2.3 Automation and scalability
  • 5.4.3 ADJACENT TECHNOLOGIES
    • 5.4.3.1 Nanotechnology
    • 5.4.3.2 Immunotherapy platforms
• 5.5 PRICING ANALYSIS
  • 5.5.1 AVERAGE SELLING PRICE TREND OF CELL THERAPY PRODUCTS, BY KEY PLAYER, 2022-2024
  • 5.5.2 AVERAGE SELLING PRICE TREND OF CELL THERAPY EQUIPMENT, BY REGION, 2022-2024
• 5.6 VALUE CHAIN ANALYSIS
• 5.7 PATENT ANALYSIS
• 5.8 TRADE ANALYSIS
  • 5.8.1 IMPORT DATA FOR MACHINES AND APPARATUS FOR ELECTROPLATING, ELECTROLYSIS, OR ELECTROPHORESIS (HS CODE: 854330)
  • 5.8.2 EXPORT DATA FOR MACHINES AND APPARATUS FOR ELECTROPLATING, ELECTROLYSIS, OR ELECTROPHORESIS (HS CODE: 854330)
• 5.9 KEY CONFERENCES AND EVENTS, 2025-2026
• 5.10 REGULATORY LANDSCAPE
  • 5.10.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.10.2 REGULATORY FRAMEWORK
    • 5.10.2.1 North America
    • 5.10.2.2 Europe
    • 5.10.2.3 Asia Pacific
    • 5.10.2.4 Rest of the World
• 5.11 PORTER'S FIVE FORCES ANALYSIS
  • 5.11.1 THREAT OF NEW ENTRANTS
  • 5.11.2 THREAT OF SUBSTITUTES
  • 5.11.3 BARGAINING POWER OF BUYERS
  • 5.11.4 BARGAINING POWER OF SUPPLIERS
  • 5.11.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.12 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.12.1 KEY STAKEHOLDERS
  • 5.12.2 BUYING CRITERIA
• 5.13 INVESTMENT & FUNDING SCENARIO
• 5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESSES
• 5.15 IMPACT OF AI/GEN AI ON CELL THERAPY TECHNOLOGIES MARKET

6 CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT

• 6.1 INTRODUCTION
• 6.2 MEDIA, SERA, AND REAGENTS
  • 6.2.1 IMPORTANCE OF MEDIA, SERA, AND REAGENTS IN CELL PROCESSING TO DRIVE MARKET
• 6.3 CELL THERAPY EQUIPMENT
  • 6.3.1 CELL PROCESSING EQUIPMENT
    • 6.3.1.1 Development of automated and closed-system cell processing equipment to accelerate segment growth
  • 6.3.2 SINGLE-USE EQUIPMENT
    • 6.3.2.1 Increasing funding for stem cell therapy to drive market
  • 6.3.3 OTHER CELL THERAPY EQUIPMENT
• 6.4 SYSTEMS & SOFTWARE
  • 6.4.1 RISING DEMAND FOR CELL THERAPIES TO SUPPORT MARKET GROWTH
• 6.5 CELL CULTURE VESSELS
  • 6.5.1 RISING R&D AND INVESTMENTS IN CELL-BASED THERAPIES TO DRIVE DEMAND
• 6.6 CELL ENGINEERING PRODUCTS
  • 6.6.1 AVAILABILITY OF WIDE RANGE OF CELL ENGINEERING PRODUCTS TO SUPPORT MARKET
• 6.7 OTHER PRODUCTS

7 CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS

• 7.1 INTRODUCTION
• 7.2 CELL PROCESSING
  • 7.2.1 CELL EXPANSION
    • 7.2.1.1 Rising demand for personalized and regenerative therapies to drive market growth
  • 7.2.2 CELL ISOLATION
    • 7.2.2.1 Rising need for scalable, efficient isolation technologies to drive market
  • 7.2.3 CELL CHARACTERIZATION
    • 7.2.3.1 Increasing demand for high-quality, safe, and effective cell-based therapies to propel growth
  • 7.2.4 CELL COLLECTION
    • 7.2.4.1 Advancements in cell collection technologies to drive market
• 7.3 CELL PRESERVATION
  • 7.3.1 ADVANCEMENT IN CRYOPRESERVATION TECHNOLOGIES TO DRIVE GROWTH
• 7.4 PROCESS MONITORING & QUALITY CONTROL
  • 7.4.1 INCREASING DEMAND FOR AUTOMATED QUALITY CONTROL IN CELL THERAPY PRODUCTION TO DRIVE MARKET
• 7.5 CELL HANDLING
  • 7.5.1 INCREASING DEMAND FOR AUTOMATED, EFFICIENT, AND SCALABLE SOLUTIONS TO DRIVE MARKET GROWTH
• 7.6 CELL DISTRIBUTION
  • 7.6.1 INCREASED FOCUS ON TRANSPORTATION AND STORAGE TO DRIVE MARKET GROWTH

8 CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE

• 8.1 INTRODUCTION
• 8.2 T CELLS
  • 8.2.1 RISING RESEARCH ON CAR T-CELL THERAPY TO ACCELERATE GROWTH
• 8.3 STEM CELLS
  • 8.3.1 INCREASING FUNDING FOR STEM CELL RESEARCH TO PROPEL MARKET
• 8.4 OTHER CELLS

9 CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION

• 9.1 INTRODUCTION
• 9.2 CANCER
  • 9.2.1 RISING RESEARCH ON CAR T-CELL THERAPY TO ACCELERATE SEGMENT GROWTH
• 9.3 CARDIOVASCULAR DISEASE
  • 9.3.1 INCREASING FOCUS ON INNOVATIVE CELL THERAPY APPROACHES TO DRIVE MARKET
• 9.4 ORTHOPEDIC DISORDERS
  • 9.4.1 INCREASING FOCUS ON STEM CELL THERAPY FOR TISSUE REGENERATION TO DRIVE MARKET
• 9.5 AUTOIMMUNE DISEASES
  • 9.5.1 INCREASING FUNDING FOR STEM CELL RESEARCH TO SUPPORT MARKET GROWTH
• 9.6 OTHER APPLICATIONS

10 CELL THERAPY TECHNOLOGIES MARKET, BY END USER

• 10.1 INTRODUCTION
• 10.2 BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 10.2.1 INCREASING ADOPTION OF INORGANIC GROWTH STRATEGIES BY BIOPHARMACEUTICAL COMPANIES TO DRIVE MARKET
• 10.3 CROS & CMOS
  • 10.3.1 FOCUS ON OUTSOURCING TO DRIVE SEGMENT GROWTH
• 10.4 RESEARCH INSTITUTES
  • 10.4.1 RISING RESEARCH ACTIVITY TO SUPPORT MARKET GROWTH
• 10.5 CELL BANKS
  • 10.5.1 INCREASING DEMAND FOR STANDARDIZED CELL LINES TO SUPPORT MARKET GROWTH

11 CELL THERAPY TECHNOLOGIES MARKET, BY REGION

• 11.1 INTRODUCTION
• 11.2 NORTH AMERICA
  • 11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 11.2.2 US
    • 11.2.2.1 US dominates North American cell therapy technologies market
  • 11.2.3 CANADA
    • 11.2.3.1 Increasing government funding to drive adoption of cell therapy instruments
• 11.3 EUROPE
  • 11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 11.3.2 GERMANY
    • 11.3.2.1 Germany to hold largest market share
  • 11.3.3 UK
    • 11.3.3.1 Favorable funding & investment scenario to drive market growth
  • 11.3.4 FRANCE
    • 11.3.4.1 Availability of government & private funding to support market growth
  • 11.3.5 ITALY
    • 11.3.5.1 Increasing R&D, public & private investment, and support to offer growth opportunities
  • 11.3.6 SPAIN
    • 11.3.6.1 Advancement in personalized medicine to stimulate market
  • 11.3.7 REST OF EUROPE
• 11.4 ASIA PACIFIC
  • 11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 11.4.2 CHINA
    • 11.4.2.1 Increasing R&D expenditure to drive market growth
  • 11.4.3 JAPAN
    • 11.4.3.1 Strong availability of funding to support market growth
  • 11.4.4 INDIA
    • 11.4.4.1 Rising funding programs to drive market
  • 11.4.5 AUSTRALIA
    • 11.4.5.1 Increasing government funding & initiatives to drive market growth
  • 11.4.6 SOUTH KOREA
    • 11.4.6.1 Alliances & investments in research to drive market
  • 11.4.7 REST OF ASIA PACIFIC
• 11.5 LATIN AMERICA
  • 11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 11.5.2 BRAZIL
    • 11.5.2.1 Brazil to dominate Latin American market till 2029
  • 11.5.3 MEXICO
    • 11.5.3.1 Strong pharmaceutical industry and increased government support to augment market
  • 11.5.4 REST OF LATIN AMERICA
• 11.6 MIDDLE EAST
  • 11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
  • 11.6.2 GCC COUNTRIES
    • 11.6.2.1 Saudi Arabia
      • 11.6.2.1.1 Increasing government investments in healthcare and growing pharmaceuticals industry to support market
    • 11.6.2.2 UAE
      • 11.6.2.2.1 Growing R&D expenditure & well-established class infrastructure to drive market
    • 11.6.2.3 Rest of GCC Countries
  • 11.6.3 REST OF MIDDLE EAST
• 11.7 AFRICA
  • 11.7.1 MACROECONOMIC OUTLOOK FOR AFRICA

12 COMPETITIVE LANDSCAPE

• 12.1 OVERVIEW
• 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN CELL THERAPY TECHNOLOGIES MARKET
• 12.3 REVENUE ANALYSIS
• 12.4 MARKET SHARE ANALYSIS
• 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 12.5.1 STARS
  • 12.5.2 EMERGING LEADERS
  • 12.5.3 PERVASIVE PLAYERS
  • 12.5.4 PARTICIPANTS
  • 12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 12.5.5.1 Company footprint
    • 12.5.5.2 Region footprint
    • 12.5.5.3 Product footprint
    • 12.5.5.4 Process footprint
    • 12.5.5.5 Cell type footprint
    • 12.5.5.6 Application footprint
• 12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 12.6.1 PROGRESSIVE COMPANIES
  • 12.6.2 RESPONSIVE COMPANIES
  • 12.6.3 DYNAMIC COMPANIES
  • 12.6.4 STARTING BLOCKS
  • 12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
• 12.7 COMPANY VALUATION & FINANCIAL METRICS
  • 12.7.1 FINANCIAL METRICS
  • 12.7.2 COMPANY VALUATION
• 12.8 BRAND/PRODUCT COMPARISON
• 12.9 COMPETITIVE SCENARIO
  • 12.9.1 PRODUCT LAUNCHES
  • 12.9.2 DEALS
  • 12.9.3 EXPANSIONS

13 COMPANY PROFILES

• 13.1 KEY PLAYERS
  • 13.1.1 DANAHER CORPORATION
    • 13.1.1.1 Business overview
    • 13.1.1.2 Products offered
    • 13.1.1.3 Recent developments
      • 13.1.1.3.1 Product launches
      • 13.1.1.3.2 Deals
      • 13.1.1.3.3 Expansions
    • 13.1.1.4 MnM view
      • 13.1.1.4.1 Key strengths
      • 13.1.1.4.2 Strategic choices
      • 13.1.1.4.3 Weaknesses and competitive threats
  • 13.1.2 MERCK KGAA
    • 13.1.2.1 Business overview
    • 13.1.2.2 Products offered
    • 13.1.2.3 Recent developments
      • 13.1.2.3.1 Deals
      • 13.1.2.3.2 Expansions
    • 13.1.2.4 MnM view
      • 13.1.2.4.1 Key strengths
      • 13.1.2.4.2 Strategic choices
      • 13.1.2.4.3 Weaknesses and competitive threats
  • 13.1.3 THERMO FISHER SCIENTIFIC INC.
    • 13.1.3.1 Business overview
    • 13.1.3.2 Products offered
    • 13.1.3.3 Recent developments
      • 13.1.3.3.1 Product launches
      • 13.1.3.3.2 Deals
      • 13.1.3.3.3 Expansions
    • 13.1.3.4 MnM view
      • 13.1.3.4.1 Key strengths
      • 13.1.3.4.2 Strategic choices
      • 13.1.3.4.3 Weaknesses and competitive threats
  • 13.1.4 LONZA
    • 13.1.4.1 Business overview
    • 13.1.4.2 Products offered
    • 13.1.4.3 Recent developments
      • 13.1.4.3.1 Product launches
      • 13.1.4.3.2 Deals
  • 13.1.5 SARTORIUS AG
    • 13.1.5.1 Business overview
    • 13.1.5.2 Products offered
    • 13.1.5.3 Recent developments
      • 13.1.5.3.1 Product launches
      • 13.1.5.3.2 Deals
      • 13.1.5.3.3 Expansions
  • 13.1.6 AGILENT TECHNOLOGIES, INC.
    • 13.1.6.1 Business overview
    • 13.1.6.2 Products offered
    • 13.1.6.3 Recent developments
      • 13.1.6.3.1 Product launches
      • 13.1.6.3.2 Deals
  • 13.1.7 AVANTOR, INC.
    • 13.1.7.1 Business overview
    • 13.1.7.2 Products offered
    • 13.1.7.3 Recent developments
      • 13.1.7.3.1 Deals
  • 13.1.8 FRESENIUS SE & CO. KGAA
    • 13.1.8.1 Business overview
    • 13.1.8.2 Products offered
    • 13.1.8.3 Recent developments
      • 13.1.8.3.1 Deals
  • 13.1.9 BECTON, DICKINSON AND COMPANY
    • 13.1.9.1 Business overview
    • 13.1.9.2 Products offered
    • 13.1.9.3 Recent developments
      • 13.1.9.3.1 Product launches
  • 13.1.10 CORNING INCORPORATED
    • 13.1.10.1 Business overview
    • 13.1.10.2 Products offered
  • 13.1.11 TERUMO CORPORATION
    • 13.1.11.1 Business overview
    • 13.1.11.2 Products offered
    • 13.1.11.3 Recent developments
      • 13.1.11.3.1 Product launches
      • 13.1.11.3.2 Deals
      • 13.1.11.3.3 Expansions
  • 13.1.12 BIO-TECHNE
    • 13.1.12.1 Business overview
    • 13.1.12.2 Products offered
    • 13.1.12.3 Recent developments
      • 13.1.12.3.1 Product launches
      • 13.1.12.3.2 Deals
      • 13.1.12.3.3 Other developments
  • 13.1.13 GENSCRIPT
    • 13.1.13.1 Business overview
    • 13.1.13.2 Products offered
    • 13.1.13.3 Recent developments
      • 13.1.13.3.1 Deals
  • 13.1.14 MAXCYTE
    • 13.1.14.1 Business overview
    • 13.1.14.2 Products offered
    • 13.1.14.3 Recent developments
      • 13.1.14.3.1 Deals
  • 13.1.15 STEMCELL TECHNOLOGIES
    • 13.1.15.1 Business overview
    • 13.1.15.2 Products offered
    • 13.1.15.3 Recent developments
      • 13.1.15.3.1 Product launches
      • 13.1.15.3.2 Deals
• 13.2 OTHER PLAYERS
  • 13.2.1 OXFORD BIOMEDICA PLC
  • 13.2.2 ROOSTERBIO, INC.
  • 13.2.3 TRAKCEL
  • 13.2.4 L7 INFORMATICS, INC.
  • 13.2.5 MILTENYI BIOTEC
  • 13.2.6 REPLIGEN CORPORATION
  • 13.2.7 MAK SYSTEM
  • 13.2.8 ORIGEN BIOMEDICAL, INC.
  • 13.2.9 IXCELLS BIOTECHNOLOGIES
  • 13.2.10 KORBER AG

14 APPENDIX

• 14.1 DISCUSSION GUIDE
• 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 14.3 CUSTOMIZATION OPTIONS
• 14.4 RELATED REPORTS
• 14.5 AUTHOR DETAILS